Monk P - Search Results

1

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A. Collier KA, et al. Among authors: monk p. Cancer Chemother Pharmacol. 2021 May;87(5):599-611. doi: 10.1007/s00280-020-04229-3. Epub 2021 Jan 25. Cancer Chemother Pharmacol. 2021. PMID: 33492438 Free PMC article. Clinical Trial.

2

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.

Nadella P, Shapiro C, Otterson GA, Hauger M, Erdal S, Kraut E, Clinton S, Shah M, Stanek M, Monk P, Villalona-Calero MA. Nadella P, et al. Among authors: monk p. J Clin Oncol. 2002 Jun 1;20(11):2616-23. doi: 10.1200/JCO.2002.22.030. J Clin Oncol. 2002. PMID: 12039922 Clinical Trial.

3

Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy.

Dangle PP, Wang WP, Mayerson J, Mortazavi A, Monk P. Dangle PP, et al. Among authors: monk p. World J Surg Oncol. 2008 Sep 30;6:103. doi: 10.1186/1477-7819-6-103. World J Surg Oncol. 2008. PMID: 18826578 Free PMC article.

4

A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.

Martin LK, Bekaii-Saab T, Serna D, Monk P, Clinton SK, Grever MR, Kraut EH. Martin LK, et al. Among authors: monk p. Onkologie. 2013;36(11):657-60. doi: 10.1159/000355665. Epub 2013 Oct 14. Onkologie. 2013. PMID: 24192770 Clinical Trial.

5

A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE 3rd, Tahiri S, Bhinder A, Clinton SK, Olencki T. Monk P, et al. J Immunother. 2014 Apr;37(3):180-6. doi: 10.1097/CJI.0000000000000023. J Immunother. 2014. PMID: 24598448 Free PMC article. Clinical Trial.

6

Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Mikhail S, et al. Among authors: monk p. Cancer Chemother Pharmacol. 2015 Nov;76(5):1005-12. doi: 10.1007/s00280-015-2877-6. Epub 2015 Sep 28. Cancer Chemother Pharmacol. 2015. PMID: 26416564 Clinical Trial.

7

Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).

Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. Pili R, et al. Among authors: monk p. Clin Cancer Res. 2017 Dec 1;23(23):7199-7208. doi: 10.1158/1078-0432.CCR-17-1178. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939740 Free PMC article. Clinical Trial.

8

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Monk P, et al. Invest New Drugs. 2018 Oct;36(5):919-926. doi: 10.1007/s10637-018-0630-9. Epub 2018 Aug 7. Invest New Drugs. 2018. PMID: 30083962 Free PMC article. Clinical Trial.

9

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer.

Yin M, Zhao J, Monk P, Martin D, Folefac E, Joshi M, Jin N, Mortazavi A, Verschraegen C, Clinton S. Yin M, et al. Among authors: monk p. Cancer Med. 2020 Jan;9(1):27-34. doi: 10.1002/cam4.2605. Epub 2019 Nov 7. Cancer Med. 2020. PMID: 31697452 Free PMC article.

10

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.

Yin M, Grivas P, Wang QE, Mortazavi A, Emamekhoo H, Holder SL, Drabick JJ, Woo MS, Pal S, Vasekar M, Folefac E, Clinton SK, Monk P, Joshi M. Yin M, et al. Among authors: monk p. Oncologist. 2020 Aug;25(8):680-688. doi: 10.1634/theoncologist.2019-0851. Epub 2020 May 13. Oncologist. 2020. PMID: 32275806 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters